Search Results - HUPPERTZ, Eduard

  • Showing 1 - 11 results of 11
Refine Results
  1. 1
    Immunotherapies in the German healthcare system : Economic aspects of established antibodies and recently available therapies

    Immunotherapies in the German healthcare system : Economic aspects of established antibodies and recently available therapies by Huppertz, Eduard

    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Economic burden of vulvar and vaginal intraepithelial neoplasia: retrospective cost study at a German dysplasia centre

    Economic burden of vulvar and vaginal intraepithelial neoplasia: retrospective cost study at a German dysplasia centre by Hampl, Monika, Huppertz, Eduard, Schulz-Holstege, Olaf, Kok, Patrick, Schmitter, Sarah

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    Immuntherapien im deutschen Gesundheitswesen: Ökonomische Aspekte etablierter Antikörper und neuerer Therapien

    Immuntherapien im deutschen Gesundheitswesen: Ökonomische Aspekte etablierter Antikörper und neuerer Therapien by Huppertz, Eduard

    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Immuntherapien im deutschen Gesundheitswesen

    Immuntherapien im deutschen Gesundheitswesen by Huppertz, Eduard Dr

    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Cost effectiveness of enoxaparin as prophylaxis against venous thromboembolic complications in acutely ill medical inpatients : Modelling study from the hospital perspective in Germany

    Cost effectiveness of enoxaparin as prophylaxis against venous thromboembolic complications in acutely ill medical inpatients : Modelling study from the hospital perspective in Ger... by SCHÄDLICH, Peter K, KENTSCH, Michael, WEBER, Manfred, KÄMMERER, Wolfgang, GEORG BRECHT, Josef, NADIPELLI, Vijay, HUPPERTZ, Eduard

    Published in PharmacoEconomics
    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:
  6. 6
    Cost effectiveness of ramipril in patients at high risk for cardiovascular events: Economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for germany from the statutory health Insurance perspective

    Cost effectiveness of ramipril in patients at high risk for cardiovascular events: Economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for germany from the... by SCHÄDLICH, Peter K, BRECHT, Josef Georg, RANGOONWALA, Badrudin, HUPPERTZ, Eduard

    Published in PharmacoEconomics
    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:
  7. 7
    Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany. I. Selected DMARDs and patient-related costs

    Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany. I. Selected DMARDs and patient-related costs by SCHÄDLICH, Peter K, ZEIDLER, Henning, ZINK, Angela, GROMNICA-IHLE, Erika, SCHNEIDER, Matthias, STRAUB, Christoph, BRECHT, Josef G, HUPPERTZ, Eduard

    Published in PharmacoEconomics
    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:
  8. 8
    Economic evaluation of enoxaparin for anticoagulation in early cardioversion of persisting nonvalvular atrial fibrillation: a statutory health insurance perspective from Germany

    Economic evaluation of enoxaparin for anticoagulation in early cardioversion of persisting nonvalvular atrial fibrillation: a statutory health insurance perspective from Germany by Schädlich, Peter K, Schmidt-Lucke, Caroline, Huppertz, Eduard, Lehmacher, Walter, Nixdorff, Uwe, Stellbrink, Christoph, Brecht, Josef Georg

    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:
  9. 9
    Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide for rheumatoid arthritis in Germany. II. The contribution of leflunomide to efficiency

    Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide for rheumatoid arthritis in Germany. II. The contribution of leflunomide to efficien... by SCHÄDLICH, Peter K, ZEIDLER, Henning, ZINK, Angela, GROMNICA-IHLE, Erika, SCHNEIDER, Matthias, STRAUB, Christoph, BRECHT, Josef G, HUPPERTZ, Eduard

    Published in PharmacoEconomics
    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:
  10. 10
    Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance

    Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the... by Schädlich, P K, Brecht, J G, Brunetti, M, Pagano, E, Rangoonwala, B, Huppertz, E

    Published in PharmacoEconomics
    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:
  11. 11
    Cost-effectiveness analysis of ramipril in heart failure after myocardial infarction. Economic evaluation of the Acute Infarction Ramipril Efficacy (AIRE) study for Germany from the perspective of Statutory Health Insurance

    Cost-effectiveness analysis of ramipril in heart failure after myocardial infarction. Economic evaluation of the Acute Infarction Ramipril Efficacy (AIRE) study for Germany from th... by Schädlich, P K, Huppertz, E, Brecht, J G

    Published in PharmacoEconomics
    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:

Search Tools: